Prognostic value of protein inhibitor of activated STAT3 in breast cancer patients receiving hormone therapy

详细信息    查看全文

• 作者：Sheau-Fang Yang ; Ming-Feng Hou ; Fang-Ming Chen ; Fu Ou-Yang ; Yang-Chang Wu…
• 关键词：Breast cancer ; Protein inhibitor of activated STAT3 ; Estrogen receptor ; Cyclin D1 ; Tamoxifen
• 刊名：BMC Cancer
• 出版年：2016
• 出版时间：December 2016
• 年：2016
• 卷：16
• 期：1
• 全文大小：1,097 KB
• 参考文献：1.Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE. Stat3 activation is required for cellular transformation by v-src. Mol Cell Biol. 1998;18(5):2553–8.PubMed PubMedCentral CrossRef
  2.Ogata Y, Osaki T, Naka T, Iwahori K, Furukawa M, Nagatomo I, et al. Overexpression of PIAS3 suppresses cell growth and restores the drug sensitivity of human lung cancer cells in association with PI3-K/Akt inactivation. Neoplasia. 2006;8(10):817–25.PubMed PubMedCentral CrossRef
  3.Dabir S, Kluge A, Kresak A, Yang M, Fu P, Groner B, et al. Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival. Clin Cancer Res. 2014;20(19):5124–32.PubMed CrossRef
  4.Zhang Q, Raghunath PN, Xue L, Majewski M, Carpentieri DF, Odum N, et al. Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol. 2002;168(1):466–74.PubMed CrossRef
  5.Wible BA, Wang L, Kuryshev YA, Basu A, Haldar S, Brown AM. Increased K+ efflux and apoptosis induced by the potassium channel modulatory protein KChAP/PIAS3beta in prostate cancer cells. J Biol Chem. 2002;277(20):17852–62.PubMed CrossRef
  6.Chung CD, Liao J, Liu B, Rao X, Jay P, Berta P, et al. Specific inhibition of Stat3 signal transduction by PIAS3. Science. 1997;278(5344):1803–5.PubMed CrossRef
  7.Dolled-Filhart M, Camp RL, Kowalski DP, Smith BL, Rimm DL. Tissue microarray analysis of signal transducers and activators of transcription 3 (Stat3) and phospho-Stat3 (Tyr705) in node-negative breast cancer shows nuclear localization is associated with a better prognosis. Clin Cancer Res. 2003;9(2):594–600.PubMed
  8.Sonnenblick A, Shriki A, Galun E, Axelrod JH, Daum H, Rottenberg Y, et al. Tissue microarray-based study of patients with lymph node-positive breast cancer shows tyrosine phosphorylation of signal transducer and activator of transcription 3 (tyrosine705-STAT3) is a marker of good prognosis. Clin Transl Oncol. 2012;14(3):232–6.PubMed CrossRef
  9.Sato T, Neilson LM, Peck AR, Liu C, Tran TH, Witkiewicz A, et al. Signal transducer and activator of transcription-3 and breast cancer prognosis. Am J Cancer Res. 2011;1(3):347–55.PubMed PubMedCentral
  10.Park YY, Kim K, Kim SB, Hennessy BT, Kim SM, Park ES, et al. Reconstruction of nuclear receptor network reveals that NR2E3 is a novel upstream regulator of ESR1 in breast cancer. EMBO Mol Med. 2012;4(1):52–67.PubMed PubMedCentral CrossRef
  11.Sentis S, Le Romancer M, Bianchin C, Rostan MC, Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity. Mol Endocrinol. 2005;19(11):2671–84.PubMed CrossRef
  12.Wang LH, Yang XY, Mihalic K, Xiao W, Li D, Farrar WL. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J Biol Chem. 2001;276(34):31839–44.PubMed CrossRef
  13.Jiang R, Jin Z, Liu Z, Sun L, Wang L, Li K. Correlation of activated STAT3 expression with clinicopathologic features in lung adenocarcinoma and squamous cell carcinoma. Mol Diagn Ther. 2011;15(6):347–52.PubMed CrossRef
  14.Azare J, Doane A, Leslie K, Chang Q, Berishaj M, Nnoli J, et al. Stat3 mediates expression of autotaxin in breast cancer. PLoS One. 2011;6(11):e27851.PubMed PubMedCentral CrossRef
  15.Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer. 2011;11:506.PubMed PubMedCentral CrossRef
  16.Yeh YT, Ou-Yang F, Chen IF, Yang SF, Su JH, Hou MF, et al. Altered p-JAK1 expression is associated with estrogen receptor status in breast infiltrating ductal carcinoma. Oncol Rep. 2007;17(1):35–9.PubMed
  17.Wang SN, Yeh YT, Yu ML, Wang CL, Lee KT. Serum adiponectin levels in cholesterol and pigment cholelithiasis. Br J Surg. 2006;93(8):981–6.PubMed CrossRef
  18.Yang SF, Wang SN, Wu CF, Yeh YT, Chai CY, Chunag SC, et al. Altered p-STAT3 (tyr705) expression is associated with histological grading and intratumour microvessel density in hepatocellular carcinoma. J Clin Pathol. 2007;60(6):642–8.PubMed PubMedCentral CrossRef
  19.Bromberg J. Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development. Breast Cancer Res. 2000;2(2):86–90.PubMed PubMedCentral CrossRef
  20.Liu LM, Yan MG, Yang DH, Sun WW, Zhang JX. PIAS3 expression in human gastric carcinoma and its adjacent non-tumor tissues. Clin Res Hepatol Gastroenterol. 2011;35(5):393–8.PubMed CrossRef
  21.Kluge A, Dabir S, Vlassenbroeck I, Eisenberg R, Dowlati A. Protein inhibitor of activated STAT3 expression in lung cancer. Mol Oncol. 2011;5(3):256–64.PubMed PubMedCentral CrossRef
  22.Borghouts C, Tittmann H, Delis N, Kirchenbauer M, Brill B, Groner B. The intracellular delivery of a recombinant peptide derived from the acidic domain of PIAS3 inhibits STAT3 transactivation and induces tumor cell death. Mol Cancer Res. 2010;8(4):539–53.PubMed CrossRef
  23.Kluge A, Dabir S, Kern J, Nethery D, Halmos B, Ma P, et al. Cooperative interaction between protein inhibitor of activated signal transducer and activator of transcription-3 with epidermal growth factor receptor blockade in lung cancer. Int J Cancer. 2009;125(7):1728–34.PubMed PubMedCentral CrossRef
  24.Liu MM, Albanese C, Anderson CM, Hilty K, Webb P, Uht RM, et al. Opposing action of estrogen receptors alpha and beta on cyclin D1 gene expression. J Biol Chem. 2002;277(27):24353–60.PubMed CrossRef
  25.Sabbah M, Courilleau D, Mester J, Redeuilh G. Estrogen induction of the cyclin D1 promoter: involvement of a cAMP response-like element. Proc Natl Acad Sci U S A. 1999;96(20):11217–22.PubMed PubMedCentral CrossRef
  
• 作者单位：Sheau-Fang Yang (1) (2)
  Ming-Feng Hou (3) (4)
  Fang-Ming Chen (3) (4) (5)
  Fu Ou-Yang (3) (4)
  Yang-Chang Wu (6) (7)
  Chee-Yin Chai (2)
  Yao-Tsung Yeh (8)
  
  1. Department of Pathology, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Zhonghua 3rd Rd, Qianjin Dist, Kaohsiung, 801, Taiwan, R O C
  2. Department of Pathology, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, No.100, Shiquan 1st Rd, Sanmin Dist, Kaohsiung, 807, Taiwan, R O C
  3. Department of Surgery, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Zhonghua 3rd Rd, Qianjin Dist, Kaohsiung, 801, Taiwan, R O C
  4. Department of Surgery, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, No. 100, Shiquan 1st Rd, Sanmin Dist, Kaohsiung, 807, Taiwan, R O C
  5. Department of Laboratory, Kaohsiung Municipal Ta-Tung Hospital, No. 68, Zhonghua 3rd Rd, Qianjin Dist, Kaohsiung, 801, Taiwan, R O C
  6. School of Pharmacy, College of Pharmacy, China Medical University, No. 91, Hsueh-Shih Road, Taichung, Taiwan, 40402, R O C
  7. Chinese Medicine Research and Development Center, China Medical University Hospital, No. 2, Yude Road, Taichung, 40447, Taiwan, R O C
  8. Department of Medical Laboratory Sciences and Biotechnology, Fooyin University, No.151, Jinxue Rd, Daliao Dist, Kaohsiung, 831, Taiwan, R O C
  
• 刊物主题：Cancer Research; Oncology; Stem Cells; Animal Models; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2407

文摘

Background Deregulated signal transducer and activator of transcription 3 (STAT3) signaling has been well documented in certain cancers. Alterations in specific negative regulators, such as protein inhibitor of activated STAT3 (PIAS3), may contribute to cancer development.